Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial

Paper. Armstrong SB, Levin AW, Sepeda ND et al.. Communications Medicine, 30 Jul 2026.

Tags: Human, Psilocybin, PTSD, Anxiety.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 10: Early pilots in veteran PTSD, phantom limb pain and bipolar II

12 US veterans with severe, treatment-resistant PTSD received two psilocybin sessions with therapy. There were no serious adverse events, and 75% were in remission a month later. Small pilots also tested psilocybin in phantom limb pain (9 people, placebo-controlled) and bipolar II depression (14 people, open-label).

How much weight it carries: Open-label or very small. These results justify larger trials; they don't show the treatment works. (Humans, n = 12, Open-label, Peer reviewed)

Read the original

—
Node—
Statuslive
Throughput—